V
Veracyte
Diagnostics for cancer
At a glance
- Status
- Listed
- Listing
- IPO 2013
Open roles
Veracyte in the San Francisco ecosystem
The Veracyte office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later6 investors entered at this stage
Kleiner Perkins- TBTPG Biotech
TPG- GVGE Ventures
Versant Ventures- DADomain Associates
Source: Dealroom Talent Intelligence.
Alumni founders
Former Veracyte employees who went on to found companies, sorted by Dealroom signal score.
PIPinkDxEst. 2022
Bonnie AndersonUnited States
Jochen KummUnited States
AQAqtualEst. 2018
Diana AbduevaUnited States
INInflammatixEst. 2016
Jonathan RomanowskyUnited States
MMMenlo MicroEst. 2016Patents
34 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Investments and acquisitions
Disclosed deals where Veracyte was the backer or acquirer, 2014–2024. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.
4 deals across Veracyte's capital deployment.
Where the deals concentrate by sector, stage, and decade.
Veracyte's portfolio, mapped.
See Veracyte on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
Veracyte acquires C2i Genomics (February 2024)
Veracyte buys Convergent Genomics to add urine-based bladder cancer test
Man Group takes new $1.31M stake in Veracyte as revenue climbs 15.5%
